Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate

Pieris Pharmaceuticals Inc PIRS announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases, at the European Respiratory Society (ERS) International Congress 2022.
Inhibition of Jagged-1/Notch 2-dependent signaling has been shown to reduce the number of secretory cells in airways, thereby reducing goblet cell metaplasia and mucus hypersecretion in ex vivo and in vivo models.
Also Read: Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs.
Pieris has generated a suite of inhaled candidates against Jagged-1, including several high-affinity antagonists across different target epitopes and biparatopic constructs with enhanced potency.
The preclinical data show that candidate molecules inhibit Jagged-1-induced Notch 2 signaling in a dose-dependent manner and demonstrate that PRS-400 reduces mucin expression ex vivo.
Additionally, PRS-400 was found in vivo to reduce mucin gene expression and goblet cells in mice with IL-13-induced airway inflammation.
The company says that PRS-400 represents a promising inhalable therapeutic drug in muco-obstructive respiratory diseases.
Price Action: PIRS shares are up 2.90% at $7.81 on the last check Wednesday.